Calcitonin Salmon Market Report 2026

The calcitonin salmon market size has grown strongly in recent years. It will grow from $1.28 billion in 2025 to $1.35 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to osteoporosis prevalence, hospital-based injectable therapies, calcium metabolism disorders, aging population, limited alternative bone therapies.

The calcitonin salmon market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to geriatric population growth, preference for non-invasive delivery, synthetic peptide innovation, bone health awareness, specialty endocrinology care. Major trends in the forecast period include continued use in osteoporosis management, preference for nasal spray formulations, shift toward synthetic and recombinant products, growth in geriatric bone disorder treatment, stable demand in hypercalcemia management.

The increasing prevalence of osteoporosis is expected to drive the growth of the calcitonin salmon market in the coming years. Osteoporosis is a medical condition characterized by reduced bone density and an elevated risk of fractures, primarily affecting older adults, especially postmenopausal women. The condition is rising due to increasing life expectancy, which results in a larger aging population more susceptible to bone density loss. Calcitonin salmon helps manage osteoporosis by inhibiting bone resorption, slowing bone loss, and maintaining bone density in affected individuals. For instance, in August 2024, according to Healthy Bones Australia, an Australia-based nonprofit organization focused on osteoporosis prevention and bone health, an estimated 6.2 million Australians aged 50 years and older - approximately 67% of this age group - were living with poor bone health in 2023, with around 23% affected by osteoporosis. Therefore, the increasing prevalence of osteoporosis is driving the growth of the calcitonin salmon market.

The rising investments in healthcare infrastructure are expected to further propel the growth of the calcitonin salmon market. Healthcare infrastructure refers to the physical and organizational facilities, such as hospitals, clinics, medical equipment, and health-system capital assets, necessary for delivering health services. Investment in healthcare infrastructure is increasing due to government initiatives aimed at modernizing facilities and expanding system capacity. Calcitonin salmon therapies benefit from this growth as expanded clinical facilities improve patient access and availability of treatment. For instance, in December 2024, according to the Centers for Medicare and Medicaid Services (CMS), a US-based federal government health data and statistical authority, U.S. healthcare spending grew by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per capita, accounting for 17.6% of the nation’s GDP. Therefore, rising healthcare infrastructure investments are driving demand for the calcitonin salmon market.

Major companies in the calcitonin salmon market are focusing on developing innovative solutions, such as calcium regulators, to improve treatment efficacy and patient outcomes. A calcium regulator is a substance that helps maintain proper calcium levels in the blood and bones, supporting bone formation, maintenance, and metabolic balance. For instance, in February 2025, Fresenius Kabi, a Germany-based pharmaceutical company, launched a USP synthetic calcitonin salmon injection to treat symptomatic Paget’s disease of the bone and hypercalcemia. This synthetic formulation is indicated for symptomatic Paget’s disease, hypercalcemia, and postmenopausal osteoporosis when alternative treatments are unsuitable. Packaged in 400 I.U./2 mL (200 I.U./mL) multi-dose vials, the product is fully formulated, filled, and packaged in the United States, reflecting Fresenius Kabi’s commitment to strengthening domestic pharmaceutical manufacturing and supply chains. The introduction of this injection enhances the company’s generic injectables portfolio, providing affordable and reliable treatment options for patients.

Major companies operating in the calcitonin salmon market are Sanofi S.A, Boehringer Ingelheim International GmbH, Viatris Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals plc, Endo International plc, Asahi Kasei Pharma Corporation, Anhui Anke Biotechnology (Group) Co. Ltd., Hybio Pharmaceutical Co. Ltd., Tokyo Chemical Industry Co. Ltd., Santa Cruz Biotechnology Inc., HRV Global Life Sciences Private Limited, AdvaCare Pharma USA LLC, BCN Peptides S.L., Leucadia Pharmaceuticals Inc., Polypeptide Group AB, LKT Laboratories Inc.

North America was the largest region in the calcitonin salmon market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin salmon market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the calcitonin salmon market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the calcitonin salmon market by increasing the cost of importing recombinant hormone ingredients, nasal spray devices, and injectable formulations. Osteoporosis and Paget’s disease treatment segments are most affected, particularly in Europe and North America where specialty hormone drugs are widely imported. Online and hospital pharmacies experience pricing pressure. However, tariffs are stimulating regional production of calcitonin formulations and nasal delivery systems, supporting long-term market stability.

The calcitonin salmon market research report is one of a series of new reports that provides calcitonin salmon market statistics, including calcitonin salmon industry global market size, regional shares, competitors with a calcitonin salmon market share, detailed calcitonin salmon market segments, market trends and opportunities, and any further data you may need to thrive in the calcitonin salmon industry. This calcitonin salmon market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Calcitonin-salmon is a synthetic or recombinant form of the hormone calcitonin, originally derived from salmon, used as a medication to help regulate calcium levels and support bone health. It works by inhibiting osteoclast activity, the cells responsible for bone breakdown, thereby slowing bone loss and lowering calcium levels in the blood.

The main types of calcitonin-salmon include nasal spray and injection. The nasal spray formulation delivers the hormone to treat conditions such as osteoporosis. These are available in various dosage forms, including intravenous, subcutaneous, nasal spray, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Applications include osteoporosis, Paget’s disease of bone, hypercalcemia, myeloma, and more, serving end-users such as clinics, pharmacies, online pharmacies, and others.

The calcitonin salmon market consists of sales of nasal spray, auto-injectors, lyophilized powder, nasal gel, and oral spray or tablet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.